THUMP domain containing 2 protein possibly induces resistance to cisplatin and 5 fluorouracil in in vitro human esophageal squamous cell carcinoma cells as revealed by transposon activation mutagenesis.
Although chemotherapy is a core treatment for esophageal cancer, some patients develop drug resistance. Gene screening with transposons, mobile genetic elements, is a novel procedure for identifying chemotherapy-resistant genes. Because transposon insertion can randomly affect nearby gene expressions. By identifying the affected genes, candidate genes can be found. This study aimed to identify Cisplatin (CDDP)/5 fluorouracil (5FU)-resistant genes in in vitro human esophageal squamous cell carcinoma (ESCC) with transposons. After establishing transposon-tagged cells, we obtained CDDP/5FU-resistant colonies. PCR (Polymerase Chain Reaction) and sequencing were used to identify the transposon inserted site and candidate of CDDP/5FU resistant genes. Focusing on one candidate gene, we confirmed the CDDP/5FU resistance by comparing the IC50 between drug resistant and wild cells. And we investigated the gene's expression by real time PCR. Finally, we mediated the candidate gene level with siRNA to confirm the resistance. Thirty-nine candidate genes for CDDP/5FU resistance were identified. Nineteen were for CDDP resistance, 27 were for 5FU resistance. Seven genes, THUMP domain-containing protein 2 (THUMPD2), nuclear factor interleukin-3-regulated protein (NFIL3), tyrosine-protein kinase transmembrane receptor 2 (ROR2), C-X-C chemokine receptor type 4 (CXCR4), thrombospondin type-1 domain-containing protein 2 (THSD7B) alpha-parvin (PARVA), and TEA domain transcription factor 1 (TEAD1) were detected as a candidate gene in both colonies. Regarding THUMPD2, its expression was downregulated, and knocking down THUMPD2 suggested drug resistance in both drugs. Thirty-nine candidate genes were identified with transposons. The downregulation of THUMPD2 was suggested to play a role in multidrug resistance in in vitro ESCC.